Dr Sleebs is a medicinal chemist with extensive experience in early-stage Drug Discovery and Chemical Biology. Dr Sleebs received his PhD from La Trobe University and joined The Walter and Eliza Hall Institute as a Research Officer in 2005. In 2018 he was appointed a Laboratory Head in the Chemical Biology Division at the Walter and Eliza Hall Institute.
His past research includes the development of anxiolytics and agents that target the BH3 family of proteins for the treatment of blood cancers. He directly contributed to collaborations with Bionomics Ltd that resulted in a Phase II clinical candidate for the treatment of anxiety and with Genentech and AbbVie developing a pre-clinical candidate for targeting blood cancers.
His current research focuses on developing small molecule probes to better understand biological processes that are essential to the survival of the malaria parasite and in collaboration with industry partners the development of novel antimalarial agents.
